Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517752 | 0.79 | OPRL1 (0.69) | OPRM1OPRL1OPRK1MEN1CYP2C9 | |
| SCHEMBL11093629 | 0.75 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL3922847 | 0.75 | OPRL1 (0.47) | OPRM1OPRL1OPRK1MEN1CYP2C9 | |
| SCHEMBL1045605 | 0.75 | OPRM1 (0.50) | SLC6A4SLC6A2OPRM1OPRL1OPRK1 | |
| SCHEMBL30404322 | 0.75 | OPRM1 (0.50) | SLC6A4SLC6A2OPRM1OPRL1OPRK1 | |
| SCHEMBL5167951 | 0.75 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2KCNH2OPRM1 | |
| SCHEMBL5164903 | 0.75 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2KCNH2OPRM1 | |
| SCHEMBL11074012 | 0.74 | OPRM1 (0.43) | SLC6A4SLC6A2OPRM1OPRL1OPRK1 | |
| SCHEMBL517439 | 0.74 | OPRL1 (0.50) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 | |
| SCHEMBL11095398 | 0.74 | SLC6A3 (0.47) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276518-B2 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| EP-1392641-B1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20040229872-A1 | Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity | GRUENENTHAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| US-20040162287-A1 | Substituted cyclohexane-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2004-08-19 | — | — | US | disclosed |
| EP-1392641-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1385493-A1 | SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089783-A1 | SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090317-A1 | SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162287-A1 | Substituted cyclohexane-1,4-diamine compounds | DPYD, DDC, QDPR | SLC6A4 819/4885SLC6A3 966/4885SLC6A2 1039/4885 |
| US-20040229872-A1 | Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity | ARG1, CD2, PDCD1 | SLC6A4 3704/4885SLC6A3 4382/4885SLC6A2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.